Method for preparing 2-[(3r)-3-methylmorpholin-4-yl]-4-[1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine
US-2021253573-A1 · Aug 19, 2021 · US
2-(morpholin-4-yl)-1,7-naphthyridines
US11529356B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11529356-B2 |
| Application number | US-202016999832-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 21, 2020 |
| Priority date | Aug 4, 2014 |
| Publication date | Dec 20, 2022 |
| Grant date | Dec 20, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib),to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treatment of a hyperproliferative disease in a human in need thereof, comprising administering an effective amount of 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine or a stereoisomer, a tautomer, or a salt thereof, or a mixture of the same, to the human. 2. The method according to claim 1 , wherein the hyperproliferative disease is cancer. 3. The method according to claim 1 , wherein the hyperproliferative disease is a sarcoma. 4. The method according to claim 1 , wherein the hyperproliferative disease is a leukemia. 5. The method according to claim 1 , wherein the hyperproliferative disease is a lymphoma. 6. The method according to claim 2 , wherein the cancer is a cancer of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, or parathyroid or a metastasis thereof. 7. The method according to claim 2 , wherein the cancer is breast cancer. 8. The method according to claim 2 , wherein the cancer is a cancer of the respiratory tract. 9. The method according to claim 2 , wherein the cancer is brain cancer. 10. The method according to claim 2 , wherein the cancer of the reproductive organs is a cancer of the male reproductive organs. 11. The method according to claim 10 , wherein the cancer is prostate cancer or testicular cancer. 12. The method according to claim 2 , wherein the cancer of the reproductive organs is a cancer of the female reproductive organs. 13. The method according to claim 12 , wherein the cancer is endometrial cancer, cervical cancer, ovarian cancer, vaginal cancer, vulvar cancer, or sarcoma of the uterus. 14. The method according to claim 2 , wherein the cancer is a cancer of the digestive tract. 15. The method according to claim 14 , wherein the cancer is anal cancer, colon cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, pancreatic cancer, rectal cancer, cancer of the small-intestine, and salivary gland cancer. 16. The method according to claim 2 , wherein the cancer is a cancer of the urinary tract. 17. The method according to claim 2 , wherein the cancer is eye cancer. 18. The method according to claim 2 , wherein the cancer is liver cancer. 19. The method according to claim 2 , wherein the cancer is skin cancer. 20. The method according to claim 2 , wherein the cancer is head-and-neck cancer.
Assignees
Inventors
Classifications
- A61K31/5377Primary
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
- A61K31/541Primary
Non-condensed thiazines containing further heterocyclic rings · CPC title
having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11529356B2 cover?
- The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib),to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment…
- Who is the assignee on this patent?
- Bayer Pharma AG
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5377. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).